Breathtaking science

Developing innovative therapeutics to transform

the standard of care for respiratory diseases
Search for better science

We aim to build a strong clinical R&D pipeline to

target debilitating respiratory diseases
Our science

Targeting respiratory diseases with significant unmet medical needs.

There are millions of patients suffering globally from chronic, debilitating respiratory conditions that are not well treated by existing medicines. There is a real and pressing need for new treatments. We are focused on developing these treatments. Our efficient R&D outsourcing model gives us access to leading experts and organisations around the globe and our agility and focus on our core competencies provide the highest standards of pre-clinical and clinical development.

See our product pipeline

Our strategy

To progress projects with high commercial potential, whilst delivering both near-and long-term value to our shareholders.

We have a clear view of the medical need and commercial potential of our novel products in global, multi-billion dollar markets. Making the right decisions now, with partners and investors, will help us identify the quickest and most effective route to market allowing us to potentially transform the lives of patients suffering from these debilating diseases, with the returns enabling us to continue this mission into the future.

Find out more about us

Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.

Latest press releases

6 November 2018

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
Initiated a Phase 2 trial o…

31 October 2018

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
Enrollment comple…

Press releases

Regulatory news

Video

Unique mechanism of action

Our breakthrough lead product, RPL554, is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases